Leap Therapeutics, Inc. (LPTX) has a consensus analyst rating of Buy, based on 4 analysts covering the stock. Of those, 3 recommend buying, 1 recommend holding, and 0 recommend selling.
The analyst consensus price target for LPTX is $5.50, representing a +614.7% upside from the current price of $0.7696. Price targets range from a low of $5.50 to a high of $5.50.
